Collapsed femoral heads caused by osteonecrosisotherwise known as avascular necrosis unfortunately represent the root cause for approximately 10% of all hip replacements nationwide. Daniel Wiznia, MD, is utilizing a stem cell treatment at Yale School of Medicine and integrating new techniques along with 3D imaging technology as part of a joint-preservation procedure.
Occurring in more than 20,000 Americans each year, osteonecrosis of the femoral head is commonly diagnosed in patients in their 30s and 40s. The disease is caused by injury of the blood supply to the head of the femur, which is the ball portion of the hips ball and socket joint.
If unaddressed, this disease may ultimately lead to the collapse of the femoral head, requiring the patient to undergo a hip replacement. For patients in this age group, a total hip replacement is not ideal as it likely will wear out and the patient will require more surgery.
The goal for each case is clear: prevent the femoral head from collapsing and the need for a hip replacement. As part of a surgical procedure, Wiznia harvests bone marrow from the patients pelvis. The individuals own stem cells are then isolated from the marrow, concentrated, and injected into lesions within the avascular portion of the femura treatment that is only taking place at some of the nations largest medical centers.
The key in these instances is to discover the avascular necrosis before the head collapses, Wiznia said. Because the vascular injury is usually a painless event, patients are generally unaware of the specific point in time when the vascular injury occurred, which is why cases are rarely discovered in time. However, we do know that 80% of patients who have avascular necrosis on one side of the hip have it on the opposite side. We usually are able to catch that second asymptomatic side in those situations and conduct the core decompression with stem cell treatment before it collapses.
According to Wiznia, this treatment reduces the risk of the head of the femur from collapsing, and the stem cell therapy has shown promising results. Soon after the procedure, many patients with avascular necrosis experience rejuvenated blood supply to the area and the bone is repopulated with new cells. This can additionally alleviate the short-term need for a hip replacement.
This novel stem cell therapy has demonstrated improved pain and function, and the stem cells decrease the risk of the femoral head from collapsing, Wiznia said. This translates into fewer young patients requiring hip replacements, and subsequent surgeries in their later years.
As an engineer himself, Wiznia works closely with the Yale School of Engineering & Applied Sciences and the Integrated 3D Surgical Team to better tailor this treatment to each specific patient.
One of the challenges of orthopaedic surgery in the human body is that surgeons are operating in a three-dimensional space and are often reliant on two-dimensional imagery such as X-rays, Wiznia added. Through the use of computer modeling, we are able to customize those images and create models that are specific to each patient, which, in turn, enhances outcomes and overall post-operative success rates.
Enhanced models and 3D imaging enable surgeons like Wiznia to better locate and target both the lesions and necrotized bone in these instances. Effectively doing so regenerates the femoral head and stimulates new osteoblast growth, which will heal the region, maintain the integrity of the joint, and decrease the chance of femoral head collapse and need for a hip replacement.
Go here to see the original:
Stem Cells Used to Treat Avascular Necrosis of the Femoral Head - Yale School of Medicine
- Cell-Based Regenerative Medicine Market Size to Witness Rapid Growth at a CAGR of 15% by 2032 | insightSLICE - EIN News - May 9th, 2023
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 21st, 2023
- Cell culture - Wikipedia - December 18th, 2022
- The Legacy of Henrietta Lacks - Hopkins Medicine - December 10th, 2022
- HOME | Stem cell & Cancer - October 4th, 2022
- CAR T Cell Therapy Offers a New Hope in the Treatment of Severe and Refractory Systemic Lupus Erythematosus - Rheumatology Network - October 4th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 4th, 2022
- Outlook on the Automated Cell Counters Global Market to 2028 - Use of Cell Counters in Personalized Medicine Presents Opportunities -... - October 4th, 2022
- Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - BioPharm International - October 4th, 2022
- Breakthrough in production of cancer-treating drug - Stanford University News - October 4th, 2022
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 4th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 4th, 2022
- 5 FDA decisions to watch in the fourth quarter - BioPharma Dive - October 4th, 2022
- bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease -... - October 4th, 2022
- Laser Focus World highlights UC research that uses light to restore cell function - University of Cincinnati - October 4th, 2022
- The Institute of Regenerative Medicine | Non-Surgical, Cell-Based ... - September 25th, 2022
- CAR T-Cell Therapy Shows Promise in Treating Lupus - Healthline - September 25th, 2022
- ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit - El Paso Inc. - September 25th, 2022
- Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit - GlobeNewswire - September 25th, 2022
- Alzheimer's disease risk linked to newly discovered protein mutation - Medical News Today - September 25th, 2022
- Biological Links Identified Between an Aggressive Breast Cancer Type and African Ancestry - Weill Cornell Medicine Newsroom - September 25th, 2022
- The Use of Nanorobotics in the Treatment Therapy of Cancer and Its Future Aspects: A Review - Cureus - September 25th, 2022
- UW Health, UW-Madison School of Medicine and Public Health: Innovative clinical trial targets recurrent BK infection in kidney transplant recipients -... - September 25th, 2022
- Shutting down backup genes leads to cancer remission in mice - University of Michigan News - September 25th, 2022
- Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges... - September 25th, 2022
- FDA's ODAC Votes That Benefits Do Not Outweigh Risks for Poziotinib in HER Exon 20 Ins+ NSCLC - Targeted Oncology - September 25th, 2022
- Courageous Lanarkshire teen who survived leukaemia thanks to a clinical trial pursues nursing dream - Daily Record - September 25th, 2022
- Discovery Reveals How the Immune System Tolerates Friendly Gut Bacteria - Weill Cornell Medicine Newsroom - September 8th, 2022
- Study: New Factors Are Associated With Increased PFS from BCMA-Targeted T-Cell Therapy - Pharmacy Times - September 8th, 2022
- Study Uncovers Possible Path for Improving T Cell Therapies - University of Arizona - September 8th, 2022
- Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study - Gilead Sciences - September 8th, 2022
- Manipulating Astrocytes in Tumor Environment Effective Against Glioblastoma - Inside Precision Medicine - September 8th, 2022
- Jane Fonda Diagnosed with Non-Hodgkin's Lymphoma: What to Know - Healthline - September 8th, 2022
- Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC - AJMC.com Managed Markets Network - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- The Role of Eosinophils as a Biomarker to Inform Treatment Decisions for Patients With COPD - Consultant360 - August 30th, 2022
- Scientists Discover Surprise Anticancer Properties of Common Lab Molecule | Newsroom - UNC Health and UNC School of Medicine - August 30th, 2022
- Overall survival is similar for patients receiving CT-based or minimal follow-up after surgical resection of non-small-cell lung cancer - 2 Minute... - August 30th, 2022
- NSF Grant to Aid OSU Researchers Developing Treatment for Canine Cancer - The Corvallis Advocate - August 30th, 2022
- Researchers Identify the Target of Immune Attacks on Liver Cells in Metabolic Disorders - Weill Cornell Medicine Newsroom - August 22nd, 2022
- Why Is CAR T-Cell Therapy One of the Most Phenomenal Advances in Science? - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms - PR Newswire - August 22nd, 2022
- Cell Analysis Global Market Report 2022: Growing Focus on Personalized Medicine & Introduction of Advanced Technologies in Cell Analysis Presents... - August 22nd, 2022
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 22nd, 2022
- Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimers Disease Patients, Findings Published in Science Translational Medicine - BioSpace - August 22nd, 2022
- Restoring cell and organ function after the heart stops - National Institutes of Health (.gov) - August 22nd, 2022
- Rolling the Dice: Gamble Pays Off For Cancer Patient in CAR T-Cell Clinical Trial - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Boosting neuron formation restores memory in mice with Alzheimer's disease - EurekAlert - August 22nd, 2022
- UTSW study finds p53 gene plays second role in suppressing genes tied to cancer - UT Southwestern - August 22nd, 2022
- GlyNAC supplementation reverses mitochondrial dysfunction, oxidative stress and aging hallmarks to boost strength and promote health in aging humans -... - August 22nd, 2022
- Multiple shots of the BCG vaccine protect type 1 diabetics from COVID-19 - EurekAlert - August 22nd, 2022
- Cell Regeneration Medicine Market Analysis by Type, Application, Growth, Demand, Status, and Forecast from 2022 to 2032 - Digital Journal - August 5th, 2022
- Higher Hydroxyurea Exposure Tied to Better Blood Parameters in US... - Sickle Cell Anemia News - August 5th, 2022
- Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here - Newshub - July 27th, 2022
- MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug - PMLiVE - July 27th, 2022
- CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure' - Medscape - July 27th, 2022
- Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated... - July 27th, 2022
- CRISPR therapeutics can damage the genome - EurekAlert - July 27th, 2022
- To cell surface and beyond: Tracing subcellular glycoprotein transport using modified cholera toxin - EurekAlert - July 27th, 2022
- From Donor to Patient: Advancing the Future of Cell Therapies - Genetic Engineering & Biotechnology News - July 27th, 2022
- Five-Year Review of Biomedical Research Imaging Center, Center Director | Newsroom - UNC Health and UNC School of Medicine - July 27th, 2022
- Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer - Yale School of Medicine - July 11th, 2022
- Stem Cell Assays Market Report 2022-2027: Increasing Awareness About Therapeutic Potency of Stem Cells Driving Growth - ResearchAndMarkets.com -... - July 11th, 2022
- Sickle cell disease could be treated with common plant, study finds - The Telegraph - July 11th, 2022
- Unexpected link between most common cancer drivers may yield more effective drugs - University of Wisconsin-Madison - July 11th, 2022
- Scientists Discover Key to Hepatitis A Virus Replication, Show Drug Effectiveness | Newsroom - UNC Health and UNC School of Medicine - July 11th, 2022
- How Erectile Dysfunction Drugs Can Help Treat Cancer and Save Thousands of Lives - SciTechDaily - July 11th, 2022
- Pune: Dr Mohan Wani appointed as director of National Centre for Cell Science - The Indian Express - July 11th, 2022
- Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma - Gilead... - July 3rd, 2022
- Important Factors for Regulating the Body's Immune Response - Neuroscience News - July 3rd, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - July 3rd, 2022
- Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with... - July 3rd, 2022
- Growing scope of Genetic Medicine and Stem Cell Research - The Hindu - June 22nd, 2022
- When children with sickle cell grow up, they face a system not designed for them - 89.3 WFPL News Louisville - June 22nd, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 22nd, 2022
- Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - June 22nd, 2022
- Bringing heart and humanity to hematology | News | Harvard TH Chan School of Public Health - HSPH News - June 22nd, 2022
- Belzutifan Improves Survival in Patients With RCC and VHL - Targeted Oncology - June 22nd, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 13th, 2022